Number of babies suffering withdrawal from opioid drugs skyrockets

As the opioid crisis continues, consequences for the children of users are beginning to come to light.

A new report published in JAMA Pediatrics found that the number of babies going through opiate withdrawal has skyrocketed, CNN reports. Babies get addicted to the drug while still in the womb of women who use opioids. When the babies are born, they aren’t getting the drug anymore, which causes withdrawal symptoms like non-stop crying, shaking, vomiting and diarrhea.

The crisis is especially prominent in rural areas. The research found that from 2004 to 2013, the proportion of babies in these areas suffering from withdrawal increased from 12.9 percent to 21.2 percent.

To read more about the crisis and how medical professionals are working to help suffering babies, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup